Source comparison
Tesamorelin + Ipamorelin Blend: Research Comparison
Tesamorelin + Ipamorelin Blend Dual-pathway GH stimulation: GHRH receptor activation + ghrelin receptor agonism Visceral adiposity research, lipodystrophy studies, body composition optimisation 15.2% VAT reduction over 26 weeks (JCEM 2022 trial) Low: transient
This comparison does not assign a generated winner or score.
- Tesamorelin + Ipamorelin Blend
- Dual-pathway GH stimulation: GHRH receptor activation + ghrelin receptor agonism
- Visceral adiposity research, lipodystrophy studies, body composition optimisation
- 15.2% VAT reduction over 26 weeks (JCEM 2022 trial)
- Low: transient water retention, mild joint stiffness, increased hunger (resolves in 2–3 weeks)
- Best choice for visceral fat-targeted research requiring sustained GH elevation without cortisol/prolactin effects
- CJC-1295 + Ipamorelin
- Modified GHRH analogue (CJC-1295 DAC) + ghrelin agonist
- Muscle preservation studies, anti-aging research, sleep quality analysis
- Moderate: 8–12% VAT reduction observed in observational studies (no RCT data)
- Low: similar to tesamorelin blend, but CJC-1295 DAC causes longer GH elevation (potential for receptor desensitization)
- Effective for general body composition research but lacks specific visceral fat efficacy data of tesamorelin
- Tesamorelin Monotherapy
- GHRH receptor activation only
- HIV-associated lipodystrophy, growth hormone deficiency research
- 10–18% VAT reduction over 6 months (FDA approval based on Phase 3 trials)
- Low: injection site reactions, peripheral edema, myalgia in <5% of subjects
- FDA-approved for lipodystrophy; strong visceral fat data but less GH output than dual-pathway blends
- Ipamorelin Monotherapy
- Ghrelin receptor agonism only
- Appetite regulation studies, muscle preservation in caloric deficit
- Minimal: no significant VAT reduction as monotherapy in published trials
- Very low: minimal cortisol/prolactin effect, transient hunger increase only
- Limited efficacy for fat loss alone; primarily used for lean mass preservation or as part of combination protocols
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist (oral bioavailable)
- Muscle wasting research, bone density studies, sleep architecture analysis
- Low: 5–8% VAT reduction in long-term trials, but paired with subcutaneous fat gain in some subjects
- Moderate: significant appetite increase, fasting glucose elevation, water retention (edema in 10–15% of subjects)
- Convenient oral administration but inferior visceral fat selectivity; appetite effects limit compliance in research settings